Rebound Hypoxemia in Mechanically Ventilated Patients With COVID-19 Completing a Standard 10-Day Course of Corticosteroid Therapy

• Published in: Respiratory care Vol. 70; no. 8; p. 987
• Main Authors: Costa-Pinto, Rahul, Rotherham, Hannah, O'Brien, Zachary, Perera, Padeepa, Chen, Vicky, Massarany, Christopher, Xu, Brett, Bellomo, Rinaldo
• Format: Journal Article
• Language: English
• Published: United States 01.08.2025
• Subjects: Adrenal Cortex Hormones - administration & dosage; Aged; Cohort Studies; COVID-19 - complications; COVID-19 - mortality; COVID-19 - therapy; COVID-19 Drug Treatment; Dexamethasone - administration & dosage; Dexamethasone - therapeutic use; Female; Glucocorticoids - administration & dosage; Humans; Hypoxia - epidemiology; Hypoxia - etiology; Intensive Care Units; Male; Middle Aged; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; COVID-19; dexamethasone; organizing pneumonia; corticosteroids; mechanical ventilation; rebound hypoxemia
• ISSN: 1943-3654
• DOI: 10.1089/respcare.12494

Rebound hypoxemia may occur after cessation of corticosteroid therapy for COVID-19 pneumonitis. We aimed to determine the incidence of this phenomenon in mechanically ventilated patients with COVID-19 completing corticosteroid therapy. We conducted a retrospective observational cohort study across 2 tertiary ICUs from September to December 2021. We included all adult patients receiving invasive mechanical ventilation on completion of a 10-day course of dexamethasone for COVID pneumonitis. Our primary outcome was change in P /F ratio in the 7 days following cessation of dexamethasone. Secondary outcomes included duration of ventilation, frequency of corticosteroid recommencement, and mortality. We studied 88 subjects. Median age was 61 years (interquartile range [IQR] 51-67), and median duration of mechanical ventilation was 14 days (IQR 11-26). On completion of dexamethasone, 62 subjects (70%) remained off corticosteroid therapy for the subsequent 7 days. Of these, 63% ( 20) had a stable P /F ratio on day 7 (mean change 197 ± 42 mm Hg to 258 ± 83 mm Hg). Subjects who had a reduction in P /F ratio >20 mm Hg by day 7 (mean change 214 ± 68 mm Hg to 152 ± 78 mm Hg) were more likely to die in hospital ( < .001). These subjects had a higher C-reactive protein level at time of steroid cessation (204 ± 87 mg/L, = .17), which remained persistently elevated (206 ± 89 mg/L, = .01) on day 7. The 30% of subjects who recommenced steroids required a longer duration of ventilation (13.5 vs 24.5 d, = .002) but showed no differences in ICU mortality (19% vs 27%, = .43). Rebound hypoxemia and steroid recommencement were common occurrences in mechanically ventilated subjects with COVID-19. Rebound hypoxemia was associated with higher mortality. Steroid recommencement was associated with longer duration of mechanical ventilation but no significant difference in mortality.